With a growing number of patients using these medications for diabetes or to meet certain optimization goals before undergoing hip and knee reconstructive surgery, our aim was to establish evidence-based guidelines on when to discontinue these to enhance patient safety and surgical success. The study, Optimal Timing for Cessation of GLP-1 Agonist Before Elective Total Hip and Knee Arthroplasty, obtained data from the TriNetX Research Network, a multi-institutional national aggregated database, to identify patients who underwent TKA or THA from January 1, 2018 to January 1, 2023
At six weeks, ten of twelve patients reported complete symptom resolution, while two achieved 80% improvement
Together, these findings support sustained obesity medication for ongoing cardiometabolic and quality-of-life benefits following initial weight loss, though the degree of weight maintenance required to preserve these improvements remains to be defined
What are the benefits of Tirzepatide in Maricopa, AZ
To see how this framework supports sustainable wellness, Read the Expert Breakdown of Sprout Health Weight Loss